Skip to main content

Patritumab deruxtecan shows promise for EGFR inhibitor-resistant NSCLC

*April 2021*

Note: This trial indicates that this might be a good treatment for post-Tagrisso progression, even in heavily pre-treated patients.

Dr. Pasi Jänne shares updated phase 1 data on the antibody–drug conjugate patritumab deruxtecan in advanced EGFR-mutated non-small-cell lung cancer patients who have developed resistance to EGFR inhibitors. Watch his presentation here.